5-Amino-1MQ Side Effects: What Studies Report

The short version: the evidence base is preclinical

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide using S-adenosyl-L-methionine as the methyl donor. Medicinal-chemistry work on this target has produced compounds built to occupy the enzyme's substrate pockets, and researchers described high-affinity alkynyl bisubstrate inhibitors of NNMT in a 2019 medicinal chemistry paper (PMID 31589440). That chemistry context matters for any discussion of side effects, because the pharmacology of this target has been explored almost entirely in enzymes, cells and rodents.

Anyone searching for a side-effect list for 5-Amino-1MQ is searching for something the literature does not contain. There is no indexed clinical trial of 5-Amino-1MQ in humans, no published dose-escalation or maximum-tolerated-dose study, and no long-term human safety follow-up. That absence is stated here as an absence rather than filled in with inference. The papers that exist were designed to test whether inhibiting NNMT changed a disease outcome in a model system, and they reported those outcomes; they were not structured as toxicology programmes with organ-weight tables, histopathology panels and graded adverse-event reporting in healthy subjects.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question, and treat everything below as a description of published research rather than guidance for use.

What animal models of NNMT inhibition reported

Several rodent studies asked whether blocking NNMT changed disease phenotypes. In a 2024 report in Diabetes, Obesity & Metabolism, researchers reported that NNMT inhibition mitigated obesity-related metabolic dysfunction in a preclinical model (PMID 39161060). A 2025 study in Physiological Reports reported that NNMT inhibition improved limb function in an experimental model of peripheral artery disease (PMID 41108586). A 2025 paper in Pharmacological Research reported that NNMT inhibition improved cardiac function and structure in a mouse model of heart failure with preserved ejection fraction (PMID 40484359).

These are efficacy findings in animals, and the study designs behind them were built around disease endpoints. Reading them as evidence of human tolerability would overstate what the authors measured. Improvement in a modelled phenotype tells a reader that the target is biologically engageable in that species and that the intervention was survivable in the experimental window; it does not describe the frequency or severity of adverse effects in people, nor does it establish anything about chronic exposure, drug interactions or use alongside other medicines.

Adverse Events and Tolerability: What Studies Report

Across the verified preclinical literature summarised here, the reported content is dominated by mechanism and efficacy rather than harm. The abstracts of the rodent studies of NNMT inhibition in metabolic dysfunction (PMID 39161060), peripheral artery disease (PMID 41108586) and heart failure with preserved ejection fraction (PMID 40484359) reported improvements in their respective endpoints without describing dose-limiting toxicity as a headline result.

An absence of reported adverse events in efficacy-focused animal abstracts is not the same as a demonstration of safety. Short-dosing rodent experiments are not powered or designed to detect uncommon, delayed or idiosyncratic harms. Human risk categories that clinical trials routinely capture — injection-site or gastrointestinal complaints, laboratory abnormalities, hepatic or renal signals, immune effects, interactions with prescribed drugs — have not been characterised for 5-Amino-1MQ in any indexed clinical study. A reader looking for that table is looking at a gap in the evidence, not a clean bill of health.

Mechanism-based questions the literature raises

Because NNMT sits at the junction of methyl-group metabolism, NAD⁺ precursor handling and gene regulation, the biology papers on this enzyme are themselves the main source of hypotheses about what systemic inhibition might do beyond the intended tissue. Three threads recur.

Immune and tumour-microenvironment biology

NNMT has been studied intensively in the cells surrounding tumours. A 2025 Nature paper reported that NNMT inhibition in cancer-associated fibroblasts restored antitumour immunity (PMID 40702186). In urothelial bladder cancer, a 2024 study reported that NNMT in cancer-associated fibroblasts drove tumour progression and resistance to immunotherapy by modulating macrophages (PMID 39067875). In gallbladder carcinoma, researchers reported that NNMT promoted M2 macrophage polarisation via IL6 and conversion of myeloid-derived suppressor cells via GM-CSF (PMID 36633260).

The relevant point for a side-effect page is directional rather than reassuring: this body of work places NNMT inside macrophage and myeloid signalling. Interventions that move immune-cell phenotypes are, in principle, interventions with immunological consequences, and none of the cited studies characterised immune function in healthy animals or humans exposed to an NNMT inhibitor.

Hepatic stress biology

The liver appears in this literature as a site where NNMT expression is dynamically regulated. A 2020 Journal of Hepatology study reported that endoplasmic reticulum stress-induced upregulation of NNMT contributed to the development of alcohol-related fatty liver (PMID 32389809). That finding positions the enzyme within hepatic stress responses, which is one reason liver endpoints are discussed as a monitoring question in reviews of this target class. What the literature does not contain is a published human hepatic-safety dataset for 5-Amino-1MQ.

Methylation, epigenetics and proliferation

NNMT consumes methyl groups, so inhibiting it alters the balance of methyl donors available to other reactions. A 2026 MedComm study reported that NNMT epigenetically activated fibronectin 1 through H3K9me3 remodelling in clear cell renal cell carcinoma (PMID 42440812), illustrating that changes in NNMT activity can register as chromatin-level changes. On the proliferation side, a 2021 paper reported that a small-molecule NNMT inhibitor showed anti-proliferative activity in HeLa cells (PMID 33645410). Anti-proliferative activity is an intended property in an oncology screen; whether comparable effects occur in normal dividing tissues at systemic exposures has not been described for 5-Amino-1MQ in humans.

Drug-response pathways

NNMT also appears in work on treatment resistance. A 2022 study reported that targeting NNMT overcame resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer cells (PMID 35387964), and a 2026 nascent-proteomics study reported that NNMT promoted drug resistance in lung cancer (PMID 40679940). Findings like these show that the enzyme intersects with how cells handle pharmacological stress, which is the mechanistic basis for asking about drug-interaction potential — a question that remains unanswered in humans for this compound.

Study-by-study overview

What the literature does not establish

• No human adverse-event frequencies. No indexed clinical trial of 5-Amino-1MQ reports rates of any side effect in people.
• No characterised dose-response for harm. The verified studies are efficacy and mechanism reports in cells and rodents, including the metabolic (PMID 39161060) and cardiac (PMID 40484359) models.
• No long-term exposure data. Chronic administration in humans has not been studied in the indexed record.
• No interaction studies. NNMT intersects with drug-response pathways in tumour cells (PMID 40679940), but clinical interaction data are absent.
• No immunological safety profile, despite the enzyme's reported role in macrophage and myeloid biology (PMID 36633260).

Regulatory and terminology context

5-Amino-1MQ is a methylquinolinium small molecule, not a peptide, even though it is often discussed alongside research peptides. It is not an approved drug product in the United States and does not appear in any approved-product labelling, which means there is no regulator-reviewed package insert listing contraindications, warnings or adverse reactions. Material circulating under this name is typically labelled for research use only, a category that carries no clinical safety review and no requirement for pharmaceutical-grade identity, purity or sterility testing. Nothing here is legal advice.

Practically, that regulatory position compounds the evidence gap described above: the compound has neither the clinical trial record that generates an adverse-event profile nor the regulatory review that would standardise what is known. Readers evaluating claims about 5-Amino-1MQ tolerability are therefore evaluating extrapolations from animal and cell experiments, and the honest summary of the literature is that it reported disease-model outcomes while leaving human safety uncharacterised.

References

• NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity (Nature, 2025)
• Nicotinamide N-methyltransferase promotes M2 macrophage polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma (Hepatology, 2023)
• ER stress-induced upregulation of NNMT contributes to alcohol-related fatty liver development (Journal of Hepatology, 2020)
• Nicotinamide N-methyltransferase inhibition improves limb function in experimental peripheral artery disease (Physiological Reports, 2025)
• Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction (Diabetes, Obesity & Metabolism, 2024)
• Nicotinamide-N-methyltransferase inhibition improves cardiac function and structure in a heart failure with preserved ejection fraction mouse model (Pharmacological Research, 2025)
• Nicotinamide N-Methyltransferase Epigenetically Activates Fibronectin 1 Through H3K9me3 Remodeling in Clear Cell Renal Cell Carcinoma (MedComm, 2026)
• Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells (Cell Death Discovery, 2022)
• Nicotinamide N-methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling (Molecular Oncology, 2026)
• Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells (Journal of Obstetrics and Gynaecology, 2021)
• NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer (Journal for ImmunoTherapy of Cancer, 2024)
• High-Affinity Alkynyl Bisubstrate Inhibitors of Nicotinamide N-Methyltransferase (NNMT) (Journal of Medicinal Chemistry, 2019)